Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALZN 
Alzamend Neuro Inc (ALZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ALZN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.83% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.57M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 2 | Beta -0.3 | 52 Weeks Range 2.06 - 17.73 | Updated Date 09/14/2025 |
52 Weeks Range 2.06 - 17.73 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -101.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -97.46% | Return on Equity (TTM) -302.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7491731 | Price to Sales(TTM) - |
Enterprise Value 7491731 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 3139860 | Shares Floating 3122717 |
Shares Outstanding 3139860 | Shares Floating 3122717 | ||
Percent Insiders 0.81 | Percent Institutions 0.07 |
Upturn AI SWOT
Alzamend Neuro Inc
Company Overview
History and Background
Alzamend Neuro, Inc. focuses on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Founded to address unmet needs in these areas, the company is involved in researching and developing innovative therapies.
Core Business Areas
- Drug Development: Focuses on the research, development, and commercialization of novel therapies for Alzheimer's disease and other neurodegenerative conditions. Currently focused on two therapeutic approaches, AL001 and AL002.
Leadership and Structure
The leadership team comprises individuals with experience in drug development, clinical research, and business management. Details on the exact organizational structure are not extensively publicized but follows a typical biotech model with research, clinical, and administrative divisions.
Top Products and Market Share
Key Offerings
- AL001: A lithium-based ionic cocrystal oral therapy being developed as a treatment for Alzheimer's, bipolar disorder, depression and post-traumatic stress disorder (PTSD). The company is pursuing clinical trials to demonstrate efficacy and safety. Market share data is currently unavailable as the product is pre-commercialization. Competitors: Other companies developing treatments for Alzheimer's, Bipolar, and Depression, including companies like Biogen (BIIB), Eli Lilly (LLY), and Axsome Therapeutics (AXSM).
- AL002: An immunotherapy product being developed for Alzheimer's disease. Market share data is currently unavailable as the product is pre-commercialization. Competitors: Other companies developing immunotherapies for Alzheimer's, including Biogen (BIIB), Roche (RHHBY), and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The neurodegenerative disease treatment market is experiencing substantial growth due to an aging global population and increasing prevalence of conditions like Alzheimer's. The market is characterized by high unmet needs and intense competition for innovative therapies.
Positioning
Alzamend Neuro is positioned as a biotechnology company focusing on developing novel treatments for challenging neurological disorders. Their competitive advantage, if any, relies on the success of their drug candidates in clinical trials and their ability to secure regulatory approvals.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of USD. Alzamend Neuro is positioned to capture a portion of this market with successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Focus on unmet medical needs
- Potential for significant market impact
Weaknesses
- Early-stage development risk
- Limited financial resources
- Dependence on clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Breakthrough therapy designations
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding risk
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
- AXSM
Competitive Landscape
Alzamend Neuro faces significant competition from larger, well-established pharmaceutical companies with greater resources and existing approved products. Their success depends on the differentiation and efficacy of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is reflected in the progress of their drug candidates through clinical trials and securing funding.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approvals of their drug candidates. Analyst projections are not readily available and would be highly speculative.
Recent Initiatives: Recent initiatives include progressing their AL001 and AL002 drug candidates through clinical trials, securing additional funding through public or private offerings, and seeking partnerships with other pharmaceutical companies.
Summary
Alzamend Neuro is a high-risk, high-reward biotechnology company focused on novel treatments for neurodegenerative diseases. Its success is heavily reliant on the outcome of clinical trials for its drug candidates. While the company's focus on unmet medical needs presents an opportunity, it faces significant competition and financial constraints. The company has to demonstrate proof of concept and raise funds to move into late-stage development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alzamend Neuro Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2021-06-15 | CEO & Director Mr. Stephan Jackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.alzamend.com |
Full time employees 4 | Website https://www.alzamend.com | ||
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.